C. difficile

Latest Headlines

Latest Headlines

Buzz on rare disease drugs puts ViroPharma in the M&A spotlight

ViroPharma's pipeline of drugs for rare diseases has reportedly stirred the interest of several pharma companies. And once word of the buyout buzz spread, the Exton, PA-based biotech's shares zoomed up 9% yesterday afternoon.

Quidel wins 510(k) for C. difficile molecular Dx

Quidel won a coveted 510(k) clearance from the FDA for a new hand-held molecular diagnostic test to detect DNA for Clostridium difficile bacteria.

Optimer inks $90M C. difficile drug pact with Astellas

Optimer is pocketing a $20 million up-front payment on a new commercial pact for its treatment for C. difficile.